The Emmes Group announced that its Board of Directors has appointed Dr. Rama Kondru as Chief Executive Officer, reflecting the company's commitment to advancing next-generation clinical trials that improve quality, speed, and patient outcomes.
This appointment reflects the Board's confidence in Dr. Kondru's ability to drive innovation and operational excellence and underscores its commitment to advancing clinical research through scientific excellence, technology, and artificial intelligence.
"It is a privilege to lead The Emmes Group at such an exciting time for our industry," said Dr. Kondru. "For nearly five decades, Emmes has stood behind some of the most important public health efforts, from the earliest NIH vaccine and infectious disease programs to the trials that helped the world respond to COVID-19. Building on that legacy, we have a unique opportunity to combine AI, technology, and clinical expertise to transform how trials are designed and conducted. Together with our customers, we will help bring life-changing therapies to patients faster while creating long-term value for customers, employees, and investors."